Preprint Article Version 1 Preserved in Portico This version is not peer-reviewed

Elexacaftor-Tezacaftor-Ivacaftor As A Final Frontier in The Treatment of Cystic Fibrosis: Definition of The Clinical and Microbiological Implications in A Case-Control Study

Version 1 : Received: 12 April 2022 / Approved: 13 April 2022 / Online: 13 April 2022 (04:06:36 CEST)

A peer-reviewed article of this Preprint also exists.

Migliorisi, G.; Collura, M.; Ficili, F.; Pensabene, T.; Bongiorno, D.; Collura, A.; Di Bernardo, F.; Stefani, S. Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study. Pharmaceuticals 2022, 15, 606. Migliorisi, G.; Collura, M.; Ficili, F.; Pensabene, T.; Bongiorno, D.; Collura, A.; Di Bernardo, F.; Stefani, S. Elexacaftor-Tezacaftor-Ivacaftor as a Final Frontier in the Treatment of Cystic Fibrosis: Definition of the Clinical and Microbiological Implications in a Case-Control Study. Pharmaceuticals 2022, 15, 606.

Abstract

The use of modulator drugs that target the cystic fibrosis transmembrane conductance regulator (CFTR) is the final frontier in the treatment of Cystic Fibrosis (CF), a genetic multiorgan disease. F508del is the most common mutation causing defective formation and function of CFTR. Elexacaftor-tezacaftor-ivacaftor is the first triple combination of CFTR modulators. Herein we report on a one-year case-control study that involved 26 patients with at least one F508del mutation. Patients were assigned to two similar groups, with patients with the worse clinical condition receiving treatment with the triple combination therapy. The study aims to define the clinical and especially microbiological implications of treatment administration. The treatment provided significant clinical benefits in terms of respiratory, pancreatic and sweat function. After one year of therapy, airway infection rates decreased and pulmonary exacerbations were dramatically reduced. Finally, treated patients reported a surprising improvement in their quality of life. The use of triple combination therapy has become essential in most CF people carrying the F508del mutation. While the clinical and instrumental benefits of treatment are thoroughly known, further investigations are needed to properly define its microbiological respiratory implications and establish the real advantage of life-long treatment with elexacaftor-tezacaftor-ivacaftor.

Keywords

Cystic Fibrosis; elexacaftor-tezacaftor-ivacaftor; microbiology; airway colonization

Subject

Biology and Life Sciences, Immunology and Microbiology

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.